% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Taverna:137076,
author = {Taverna, Mara and Straub, Tobias and Hampel, Harald and
Rujescu, Dan and Lichtenthaler, Stefan F},
title = {{A} new sandwich immunoassay for detection of the
α-secretase cleaved, soluble amyloid-β protein precursor
in cerebrospinal fluid and serum.},
journal = {Journal of Alzheimer's disease},
volume = {37},
number = {4},
issn = {1875-8908},
address = {Amsterdam},
publisher = {IOS Press},
reportid = {DZNE-2020-03398},
pages = {667-678},
year = {2013},
abstract = {Alzheimer's disease (AD) is the most common
neurodegenerative disorder. Frequently used diagnostic
biomarkers are amyloid-β42 (Aβ42), tau, and phospho-tau,
which are measured in cerebrospinal fluid (CSF), and allow a
reasonable, but not full, separation of AD patients and
controls. Besides Aβ42, additional proteolytic cleavage
products of the amyloid-β protein precursor (AβPP) have
been investigated as potential biomarkers. This includes the
α-secretase cleaved soluble AβPP ectodomain (sAβPPα).
However, some studies found a reduction of sAβPPα, whereas
other studies reported an increase of sAβPPα in the CSF of
AD patients. The divergent findings may result from the
detection of sAβPPα with antibodies, such as 6E10, which
do not exclusively detect sAβPPα, but also the alternative
β-secretase cleavage product sAβPPβ'. Here, we used the
sAβPPα-specific antibody 14D6 and developed an ELISA-like
sandwich immunoassay. The assay specifically detected
sAβPPα in cell culture supernatants, in human CSF and even
in serum, which is more readily accessible than CSF. The
assay was used to analyze sAβPPα levels in CSF and serum
of AD patients and controls. The assay detected a mild, but
significant increase in sAβPPα in the CSF of AD patients
compared to non-demented controls, while a mild reduction
was observed in serum. The 14D6 assay in CSF allowed a
better separation of AD patients from controls compared to
the 6E10 antibody. Taken together, the new assay is widely
applicable for specific sAβPPα measurement in culture
media, CSF, and serum.},
keywords = {Amino Acid Sequence / Amyloid Precursor Protein Secretases:
blood / Amyloid Precursor Protein Secretases: cerebrospinal
fluid / Amyloid Precursor Protein Secretases: genetics /
Amyloid beta-Protein Precursor: blood / Amyloid beta-Protein
Precursor: cerebrospinal fluid / Amyloid beta-Protein
Precursor: genetics / Biomarkers: blood / Biomarkers:
cerebrospinal fluid / Cell Line, Tumor / Enzyme-Linked
Immunosorbent Assay: trends / Female / Humans / Male /
Molecular Sequence Data / Registries / Amyloid beta-Protein
Precursor (NLM Chemicals) / Biomarkers (NLM Chemicals) /
Amyloid Precursor Protein Secretases (NLM Chemicals)},
cin = {AG Lichtenthaler},
ddc = {610},
cid = {I:(DE-2719)1110006},
pnm = {342 - Disease Mechanisms and Model Systems (POF3-342)},
pid = {G:(DE-HGF)POF3-342},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:23948916},
doi = {10.3233/JAD-130509},
url = {https://pub.dzne.de/record/137076},
}